In addition to being widely used to produce many recombinant proteins for basic research, the baculovirus-insect cell system can also be used to produce a variety of biologics approved for human or veterinary use. The early baculovirus expression system was technically complex and time-consuming, and the protein glycosylation pathways of insect cells were relatively primitive. Nowadays, the development of CRISPR-Cas9 for site-specific genome editing has allowed this system to be further improved. Earlier studies have shown that CRISPR can be used for gene knockout in the embryos and cell lines of Drosophila and Bombyx. Glycoengineering of CRISPR in insect cells was first demonstrated in the S2 cell line. Knockout of the N-acetylglucosaminidase gene using CRISPR resulted in a 4-fold increase in the terminal GlcNAc residues on recombinant human erythropoietin (hEPO). The same gene knockout was also reported in Sf9 cells, which was achieved through the Sf9-U6 promoter. The short time required for genome editing using CRISPR can greatly accelerate the development and application of humanized protein therapeutics in insect cell lines.
Figure 1. The timeline of approvals made by the FDA and EMA for recombinant protein therapeutics for human use overlaid with significant technological advances and regulation events.
The CRISPR-Cas9 system is a relatively new and incredibly powerful tool for site-specific genome editing. Currently, CRISPR-Cas9 vectors have been constructed and used in many different biological systems, including insect cell systems. We provide a variety of customized solutions such as many promoters to support CRISPR-Cas9 editing in insect cells (e.g., Sf9 and High Five cells) and analyze its editing efficiency and phenotypic Impact. Our proven CRISPR platform and experienced technicians guarantee the quality and efficiency of this service.
Figure 2. Comparison of the flipase-based recombination method and CRISPR for creating a stable cell line.
Creative BioMart has accumulated more than 10 years of experience in the research and application of baculovirus-insect cell system. We provide an advanced CRISPR-Cas9 technology platform to facilitate high-level expression of multiple genes in insect cells while contributing to the rapid growth of the protein therapeutics market. For more assistance, please contact us for assistance.
References